HUP0302505A2 - Peptid-deformiláz inhibitor hatású vegyületek és alkalmazásuk bakteriális fertőzések kezelésére - Google Patents

Peptid-deformiláz inhibitor hatású vegyületek és alkalmazásuk bakteriális fertőzések kezelésére

Info

Publication number
HUP0302505A2
HUP0302505A2 HU0302505A HUP0302505A HUP0302505A2 HU P0302505 A2 HUP0302505 A2 HU P0302505A2 HU 0302505 A HU0302505 A HU 0302505A HU P0302505 A HUP0302505 A HU P0302505A HU P0302505 A2 HUP0302505 A2 HU P0302505A2
Authority
HU
Hungary
Prior art keywords
group
optionally substituted
alkyl
bacterial infections
treating
Prior art date
Application number
HU0302505A
Other languages
English (en)
Inventor
Kelly M. Aubart
Jacques Briand
Siegfried B. Christensen, Iv
Maxwell David Cummings
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP0302505A2 publication Critical patent/HUP0302505A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány bakteriális fertőzések kezelési eljárására vonatkozik,amelynek során egy (I) általános képletű vegyületet - amelynekképletében X jelentése szén- vagy oxigénatom; n értéke 1 vagy 2; Arjelentése egy, a fenil-, azaindolil-, piridil-, indolil-, kinolil-,pirazinil-, benzotienil-, izoxazolil-, izokinolil-, naftil-,oxazolil-, izotiazolil-, benzotiafenil-, furil-, piridazinil-,tienil-, benzofuril-, imidazolil- és tiazolilcsoport közülkiválasztott arilcsoport; amely Ar csoport adott esetben legfeljebbhárom, a következő csoportból egymástól függetlenül kiválasztottszubsztituenst hordozhat: adott esetben szubsztituált 1-9 szénatomosalkil- vagy cikloalkilcsoport, halogénatom, 1-9 szénatomosalkoxicsoport, hidroxi-, aminocsoport, 1-9 szénatomos hidroxi-alkil-csoport, alkoxi-alkil-csoport, amelyben az alkil- és alkiléncsoportokegymástól függetlenül 1-9 szénatomot tartalmaznak, adott esetbenszubsztituált arilcsoport vagy adott estben szubsztituáltheteroarilcsoport, azaindolil-, karboxi- és/vagy alkoxi-karbonil-csoport - adnak be. Ó
HU0302505A 2000-05-05 2001-05-04 Peptid-deformiláz inhibitor hatású vegyületek és alkalmazásuk bakteriális fertőzések kezelésére HUP0302505A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20194300P 2000-05-05 2000-05-05
US23808400P 2000-10-04 2000-10-04
PCT/US2001/014593 WO2001085170A1 (en) 2000-05-05 2001-05-04 Peptide deformylase inhibitors

Publications (1)

Publication Number Publication Date
HUP0302505A2 true HUP0302505A2 (hu) 2003-12-29

Family

ID=26897227

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302505A HUP0302505A2 (hu) 2000-05-05 2001-05-04 Peptid-deformiláz inhibitor hatású vegyületek és alkalmazásuk bakteriális fertőzések kezelésére

Country Status (20)

Country Link
US (2) US6806369B2 (hu)
EP (1) EP1283711B1 (hu)
JP (1) JP2003532677A (hu)
KR (1) KR20020093127A (hu)
CN (1) CN1427721A (hu)
AR (1) AR029916A1 (hu)
AT (1) ATE389403T1 (hu)
AU (1) AU2001261218A1 (hu)
BR (1) BR0110206A (hu)
CA (1) CA2408236A1 (hu)
CZ (1) CZ20023618A3 (hu)
DE (1) DE60133273T2 (hu)
ES (1) ES2300330T3 (hu)
HU (1) HUP0302505A2 (hu)
IL (1) IL152638A0 (hu)
MX (1) MXPA02010843A (hu)
NO (1) NO20025281L (hu)
NZ (1) NZ521560A (hu)
PL (1) PL359865A1 (hu)
WO (1) WO2001085170A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328563T3 (es) * 2001-04-05 2009-11-16 Smithkline Beecham Corporation Inhibidores de peptido desformilasa.
US6852882B2 (en) * 2001-06-05 2005-02-08 Smithkline Beecham Corporation Peptide deformylase inhibitors
AU2003296960A1 (en) * 2002-12-11 2004-06-30 Smithkline Beecham Corporation Peptide deformylase inhibitors
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CN101166740B (zh) * 2005-04-25 2010-12-29 诺瓦提斯公司 用作肽脱甲酰基酶(pdf)抑制剂的咪唑并[1,2-a]吡啶衍生物
KR20080014988A (ko) * 2005-06-07 2008-02-15 노파르티스 아게 펩티드 데포르밀라제 (ｐｄｆ) 억제제 4
WO2007040289A1 (en) * 2005-10-05 2007-04-12 Promeditech Inc. Deformylase inhibitor, process for the preparation thereof, and composition comprising the same
KR100753796B1 (ko) * 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282986A (en) 1960-10-06 1966-11-01 Merck & Co Inc N-acylated hydroxamic acids and derivatives thereof
AU602485B2 (en) 1985-03-16 1990-10-18 Wellcome Foundation Limited, The Lipoxygenase and/or cyclooxygenase inhibitory compounds
GB8531838D0 (en) 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
PL154186B1 (en) 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
WO1999006361A2 (en) 1997-07-31 1999-02-11 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
BR9907689A (pt) 1998-02-07 2000-11-14 British Biotech Pharm Agentes antibacterianos
AR028075A1 (es) * 2000-05-05 2003-04-23 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US20040034024A1 (en) 2001-05-04 2004-02-19 Aubart Kelly M Peptide deformylase inhibitors

Also Published As

Publication number Publication date
KR20020093127A (ko) 2002-12-12
US6806369B2 (en) 2004-10-19
EP1283711A4 (en) 2003-05-21
WO2001085170A9 (en) 2006-01-26
EP1283711A1 (en) 2003-02-19
US20040192719A1 (en) 2004-09-30
ES2300330T3 (es) 2008-06-16
US20040053932A1 (en) 2004-03-18
IL152638A0 (en) 2003-06-24
BR0110206A (pt) 2003-01-28
NZ521560A (en) 2004-05-28
DE60133273D1 (de) 2008-04-30
WO2001085170A1 (en) 2001-11-15
AR029916A1 (es) 2003-07-23
NO20025281L (no) 2003-01-03
PL359865A1 (en) 2004-09-06
MXPA02010843A (es) 2003-03-27
NO20025281D0 (no) 2002-11-04
CN1427721A (zh) 2003-07-02
EP1283711B1 (en) 2008-03-19
CZ20023618A3 (cs) 2003-09-17
AU2001261218A1 (en) 2001-11-20
JP2003532677A (ja) 2003-11-05
DE60133273T2 (de) 2009-03-05
CA2408236A1 (en) 2001-11-15
ATE389403T1 (de) 2008-04-15
US7115605B2 (en) 2006-10-03

Similar Documents

Publication Publication Date Title
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
EA200600509A1 (ru) Соединения пиримидотиофена
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
DE69309030D1 (de) Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
NO20062185L (no) Hepatitt C virus-inhibitorer
IS6309A (is) Kínasólínafleiður
DK0920430T3 (da) Purinderivater og deres anvendelse som antikoaguleringsmidler
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
RU95102481A (ru) Способ сульфинилирования гетероциклических соединений, промежуточные сульфинамидные соединения
NO20062339L (no) Hepatitt C virus-inhibitoerer
TNSN06419A1 (en) N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
HUP0303637A2 (hu) Nitrogéntartalmú spirotriciklusos-származékok, eljárás előállításukra, valamint ezeket tartalmazó foszfodiészteráz-7-inhibitorként alkalmazható gyógyszerkészítmények
CA2439784A1 (en) Pyrazolopyrimidinone derivatives having pde7 inhibiting action
TW200617003A (en) Viral polymerase inhibitors
HUP0302505A2 (hu) Peptid-deformiláz inhibitor hatású vegyületek és alkalmazásuk bakteriális fertőzések kezelésére
PE20050371A1 (es) Inhibidores de la caspasa conteniendo anillo isoxazolinico
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
KR950703554A (ko) 피페라진 유도체 및 그의 염(piperazine derivatives and salts thereof)
MA27257A1 (fr) Composes utiles pour le traitement du charbon et l'inhibition du gene letal
BRPI0407441A (pt) 4-[(2,4-dicloro-5-metóxifenil)amino]-6-alcóxi-3-quinoli nacarbonitrilos para o tratamento de lesão isquêmica
ATE223720T1 (de) Diazepinoindole inhibitoren von phosphodiesterase iv
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren
RU2010104397A (ru) Производные изотиазола и пиразола в качестве фунгицидов

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees